Claire Mazumdar, Chief Executive Officer at Bicara Therapeutics Inc. (BCAX), sold 49,468 shares at $18.92 ($934K) on 2025-10-13, disclosed to the SEC on 2025-10-15.
Scheduled sale ($934k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.92 | 11,445 | $217K | 23.2% |
| 2 | $18.92 | 11,445 | $217K | 23.2% |
| 3 | $18.84 | 13,289 | $250K | 26.8% |
| 4 | $18.84 | 13,289 | $250K | 26.8% |
| Total | $18.88 avg | 49,468 | $934K | 100% |
| Filing → |
| BCAX | SELL | 2026-05-20 | $301K | — | Filing → |
| BCAX | SELL | 2026-04-20 | $354K | — | Filing → |
| BCAX | SELL | 2026-03-20 | $565K | — | Filing → |